Alzamend Neuro Inc (ALZN)

$2.37 +0.04 (1.72%)
Market Cap 8.86M
Revenue (ttm) 0.00
Net Income (ttm) -4.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 63,900
Avg Vol 77,676
Day's Range N/A - N/A
Shares Out 3.80M
Stochastic %K 94%
Beta -0.25
Analysts Sell
Price Target $28.00

Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-pe...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 722 6333
Address:
3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States
Noname66
Noname66 Jan. 13 at 9:25 PM
$ALZN It matters on phase 2 data report. Only have 1600 shares to gamble on that phase 2 report.
0 · Reply
hiwatt
hiwatt Jan. 13 at 8:37 PM
$ALZN Interesting quote from Carlat Publishing in their August 2025 publication.---It will take years to figure out the appropriate serum levels for lithium orotate, and by then, a new lithium salt may have stolen orotate’s aura. In 2023, the FDA greenlit trials of LiProSal, a branded lithium that—like orotate— aims to distribute more medication to the brain and less to the body. LiProSal pairs lithium with salicylate and the amino acid proline, and trials are underway in bipolar disorder, PTSD, and dementia.
0 · Reply
newVerizons
newVerizons Jan. 12 at 11:19 AM
$ALZN results will include patient improvements. .. Lithium could really help..
0 · Reply
hiwatt
hiwatt Jan. 11 at 5:19 PM
$ALZN The AI response to the role AL001 could play in AZ,--In 2026, AL001 is positioned as a potential "next-generation" lithium therapy that addresses the historical safety and delivery limitations of standard lithium Future Role in Alzheimer's Treatment If successful, AL001 could play several roles in the future landscape of Alzheimer's care: Multi-Target Neuroprotection: Unlike "single-target" drugs (like amyloid-targeting antibodies), lithium appears to work through multiple pathways, including inhibiting the GSK-3β enzyme and increasing brain-derived neurotrophic factor (BDNF). Treatment for Fragile Populations: Because of its improved safety profile, AL001 is being developed specifically for use in elderly and fragile patients who cannot tolerate traditional lithium doses. Broad Neuropsychiatric Use: Beyond Alzheimer's, AL001 is being studied for Bipolar Disorder, Major Depressive Disorder, and PTSD, potentially serving as a safer, broad-spectrum brain health stabilizer.
0 · Reply
hiwatt
hiwatt Jan. 11 at 1:44 PM
$ALZN Bottom line discussion point made from the LATTICE study,------Participants taking lithium were stable over 24 months with less deterioration in memory and attention tests; however, those in the placebo group displayed cognitive and functional decline.
0 · Reply
hiwatt
hiwatt Jan. 10 at 2:38 PM
$ALZN Here is the link to the study, but you still have to click the PDF to see the full 41 pages. Also interesting is that they mentioned that there have been 5 RCTs , the 3 longest, over one year, have demonstrated similar results concerning lithium in humans. The two shorter studies, 9-12 weeks were inconclusive, but a subanalysis did show positive data. Add this to the mouse model graph that I posted last week that was also funded by NIH and showed AL001 deposited more lihium in the brain compared to LC, as well as the recent Harvard mouse studies, and you start to have a very compelling case. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5556379
0 · Reply
hiwatt
hiwatt Jan. 10 at 2:21 PM
$ALZN The stock has been hot in 2026, so it's a good time to throw a little fuel on the fire and fan the flames. Last night I came across a (10-2025) recent published 41 page research paper detailing a 7 year clinical trial that has been funded by NIH and NIA looking at lithium carbonate and Alzheimer's. The study used the most advanced technology available today, combining cognitive assessment with neuroimaging and plasma biomarkers. Apparently 80 subjects with mild cognitive impairment were tested for two years, half LC, half placebo. The headline and I'm paraphrasing, Lithium SLOWS THE PROGRESSION OF ALZHEIMER'S and alternative formulations of lithium also warrant further investigation in human RCT since they may be effective at concentrations orders of magnitude less than lithium carbonate with much less toxicity. Folks, there are on two formulations that meet that criteria, lithium orotate and Lispro (AL001) and only one has a patent. Connect the dots!.
0 · Reply
hiwatt
hiwatt Jan. 9 at 4:41 AM
$ALZN https://www.nasdaq.com/articles/ascendiant-capital-maintains-alzamend-neuro-alzn-buy-recommendation-0
0 · Reply
hiwatt
hiwatt Jan. 9 at 4:39 AM
$ALZN
0 · Reply
hiwatt
hiwatt Jan. 6 at 4:05 PM
$ALZN If you're looking for simple answer as to why you should invest in this company, it comes down to one simple picture, which is pictured below. This picture highlights the results between the amount of lithium in the brain from the now marketed lithium carbonate and AL001 after 8 weeks of dosing mice. "IF" these results hold true in humans, then this a blockbuster drug on the way to fast approval in bipolar and alzheimer's. Note the estimated 33% increase!
0 · Reply
Latest News on ALZN
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Nov 19, 2025, 8:00 AM EST - 2 months ago

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Jul 28, 2025, 8:00 AM EDT - 6 months ago

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Jul 23, 2025, 8:00 AM EDT - 6 months ago

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Jun 16, 2025, 8:00 AM EDT - 7 months ago

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 29, 2025, 8:00 AM EDT - 8 months ago

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 19, 2025, 8:00 AM EDT - 8 months ago

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 13, 2025, 8:00 AM EDT - 8 months ago

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Reverse Stock Split

May 8, 2025, 8:00 AM EDT - 8 months ago

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

May 7, 2025, 8:00 AM EDT - 9 months ago

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Mar 25, 2025, 8:00 AM EDT - 10 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Mar 18, 2025, 8:00 AM EDT - 10 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Mar 11, 2025, 8:00 AM EDT - 11 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Mar 4, 2025, 8:10 AM EST - 11 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Feb 25, 2025, 8:00 AM EST - 11 months ago

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Aug 19, 2024, 9:41 AM EDT - 1 year ago

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

ABBV

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

May 7, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Apr 4, 2023, 6:30 AM EDT - 3 years ago

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

Nov 28, 2022, 6:30 AM EST - 3 years ago

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

Nov 22, 2022, 8:05 AM EST - 3 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

Nov 21, 2022, 7:27 PM EST - 3 years ago

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Nov 1, 2022, 6:30 AM EDT - 3 years ago

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Sep 22, 2022, 8:00 AM EDT - 3 years ago

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 17, 2021, 11:59 PM EST - 4 years ago

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Dec 17, 2021, 9:54 AM EST - 4 years ago

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

See Why Alzamend Neuro Stock Is Rallying On Thursday

Sep 30, 2021, 1:45 PM EDT - 4 years ago

See Why Alzamend Neuro Stock Is Rallying On Thursday

Why Alzamend Neuro Shares Are Surging Higher Today

Sep 30, 2021, 11:54 AM EDT - 4 years ago

Why Alzamend Neuro Shares Are Surging Higher Today

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Sep 30, 2021, 10:11 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Sep 13, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Aug 4, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Jul 30, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 28, 2021, 3:07 PM EDT - 4 years ago

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Jul 23, 2021, 7:20 AM EDT - 4 years ago

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Jul 23, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 12, 2021, 6:00 AM EDT - 4 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Jul 1, 2021, 11:23 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 1, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Jun 17, 2021, 4:30 PM EDT - 4 years ago

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Jun 16, 2021, 6:30 AM EDT - 4 years ago

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Alzamend Neuro Announces Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 4 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering

Noname66
Noname66 Jan. 13 at 9:25 PM
$ALZN It matters on phase 2 data report. Only have 1600 shares to gamble on that phase 2 report.
0 · Reply
hiwatt
hiwatt Jan. 13 at 8:37 PM
$ALZN Interesting quote from Carlat Publishing in their August 2025 publication.---It will take years to figure out the appropriate serum levels for lithium orotate, and by then, a new lithium salt may have stolen orotate’s aura. In 2023, the FDA greenlit trials of LiProSal, a branded lithium that—like orotate— aims to distribute more medication to the brain and less to the body. LiProSal pairs lithium with salicylate and the amino acid proline, and trials are underway in bipolar disorder, PTSD, and dementia.
0 · Reply
newVerizons
newVerizons Jan. 12 at 11:19 AM
$ALZN results will include patient improvements. .. Lithium could really help..
0 · Reply
hiwatt
hiwatt Jan. 11 at 5:19 PM
$ALZN The AI response to the role AL001 could play in AZ,--In 2026, AL001 is positioned as a potential "next-generation" lithium therapy that addresses the historical safety and delivery limitations of standard lithium Future Role in Alzheimer's Treatment If successful, AL001 could play several roles in the future landscape of Alzheimer's care: Multi-Target Neuroprotection: Unlike "single-target" drugs (like amyloid-targeting antibodies), lithium appears to work through multiple pathways, including inhibiting the GSK-3β enzyme and increasing brain-derived neurotrophic factor (BDNF). Treatment for Fragile Populations: Because of its improved safety profile, AL001 is being developed specifically for use in elderly and fragile patients who cannot tolerate traditional lithium doses. Broad Neuropsychiatric Use: Beyond Alzheimer's, AL001 is being studied for Bipolar Disorder, Major Depressive Disorder, and PTSD, potentially serving as a safer, broad-spectrum brain health stabilizer.
0 · Reply
hiwatt
hiwatt Jan. 11 at 1:44 PM
$ALZN Bottom line discussion point made from the LATTICE study,------Participants taking lithium were stable over 24 months with less deterioration in memory and attention tests; however, those in the placebo group displayed cognitive and functional decline.
0 · Reply
hiwatt
hiwatt Jan. 10 at 2:38 PM
$ALZN Here is the link to the study, but you still have to click the PDF to see the full 41 pages. Also interesting is that they mentioned that there have been 5 RCTs , the 3 longest, over one year, have demonstrated similar results concerning lithium in humans. The two shorter studies, 9-12 weeks were inconclusive, but a subanalysis did show positive data. Add this to the mouse model graph that I posted last week that was also funded by NIH and showed AL001 deposited more lihium in the brain compared to LC, as well as the recent Harvard mouse studies, and you start to have a very compelling case. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5556379
0 · Reply
hiwatt
hiwatt Jan. 10 at 2:21 PM
$ALZN The stock has been hot in 2026, so it's a good time to throw a little fuel on the fire and fan the flames. Last night I came across a (10-2025) recent published 41 page research paper detailing a 7 year clinical trial that has been funded by NIH and NIA looking at lithium carbonate and Alzheimer's. The study used the most advanced technology available today, combining cognitive assessment with neuroimaging and plasma biomarkers. Apparently 80 subjects with mild cognitive impairment were tested for two years, half LC, half placebo. The headline and I'm paraphrasing, Lithium SLOWS THE PROGRESSION OF ALZHEIMER'S and alternative formulations of lithium also warrant further investigation in human RCT since they may be effective at concentrations orders of magnitude less than lithium carbonate with much less toxicity. Folks, there are on two formulations that meet that criteria, lithium orotate and Lispro (AL001) and only one has a patent. Connect the dots!.
0 · Reply
hiwatt
hiwatt Jan. 9 at 4:41 AM
$ALZN https://www.nasdaq.com/articles/ascendiant-capital-maintains-alzamend-neuro-alzn-buy-recommendation-0
0 · Reply
hiwatt
hiwatt Jan. 9 at 4:39 AM
$ALZN
0 · Reply
hiwatt
hiwatt Jan. 6 at 4:05 PM
$ALZN If you're looking for simple answer as to why you should invest in this company, it comes down to one simple picture, which is pictured below. This picture highlights the results between the amount of lithium in the brain from the now marketed lithium carbonate and AL001 after 8 weeks of dosing mice. "IF" these results hold true in humans, then this a blockbuster drug on the way to fast approval in bipolar and alzheimer's. Note the estimated 33% increase!
0 · Reply
hiwatt
hiwatt Jan. 5 at 11:59 PM
$ALZN
0 · Reply
DiamondPlayz
DiamondPlayz Jan. 5 at 9:32 PM
$ALZN Are you looking for the next potential reddit squeeze? Wallstreet-bets has recently squeezed a bunch of tickers for over 500%. Make sure to put ticker MGN on your watchlist. MGN has only 1 million free float and could be the next Reddit Squeeze. Seeing a lot of talks around this one. I bought a big position for a potential reddit squeeze !"!
0 · Reply
DiamondPlayz
DiamondPlayz Jan. 5 at 5:44 PM
Seeing bulls rotate into PAVM now. Starting its massive run - Early positioning is key 💎 Low float tickers have been exploding 300% lately. Just 700k shares outstanding, don't miss PAVM ! $JAGX $HCTI $ALZN $BBAI swing
0 · Reply
Trader_L
Trader_L Jan. 2 at 12:26 AM
$ALZN wow that monthly indicator is curling upwards while showing strength. Insiders know something?
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 1 at 12:16 PM
$ALZN Current Stock Price: $1.80
0 · Reply
Scrood_the_Pooch
Scrood_the_Pooch Dec. 31 at 7:12 PM
$ALZN Sorry, forgot to include you guys too!
0 · Reply
PeteRePete
PeteRePete Dec. 31 at 4:35 PM
$ALZN wow I've had a $1.74 bid in for days and it just filled. Figured this week would be some crazy dumps all over and boy there are.
1 · Reply
hiwatt
hiwatt Dec. 31 at 1:43 PM
$ALZN
0 · Reply
hiwatt
hiwatt Dec. 31 at 1:40 PM
$ALZN Say goodbye to Todd for now. He's moved on to Gpus to the tune of $1M shares.
1 · Reply
hiwatt
hiwatt Dec. 31 at 2:13 AM
$ALZN Institutional/mutual fund shares jumped 2000% from 7354 to 151,920 in Q3 even though the stock hit a low of $2.06. It will be interesting to see how this plays out for Q4 after hitting a low of $1.87. Anyway, a couple of Warren Buffet quotes for today. "The best time to deploy capital is when things are going down" and "be fearful when others are greedy and be greedy when others are fearful".
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Dec. 30 at 11:12 PM
$ALZN completely sold out. only options left. feels so good to get cash for no work. May issue new shares next year and redo this again. free money is always nice. they will continue to buy regardless.
0 · Reply
Scrood_the_Pooch
Scrood_the_Pooch Dec. 30 at 9:09 PM
$GPUS $ALZN
0 · Reply